{"id":6363,"date":"2025-08-26T23:03:05","date_gmt":"2025-08-26T23:03:05","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/08\/26\/akeso-says-its-closely-watched-drug-improved-patient-survival-in-a-lung-cancer-trial\/"},"modified":"2025-08-26T23:03:05","modified_gmt":"2025-08-26T23:03:05","slug":"akeso-says-its-closely-watched-drug-improved-patient-survival-in-a-lung-cancer-trial","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/08\/26\/akeso-says-its-closely-watched-drug-improved-patient-survival-in-a-lung-cancer-trial\/","title":{"rendered":"STAT+: Akeso says its closely watched drug improved patient survival in a lung cancer trial"},"content":{"rendered":"

STAT+: Akeso says its closely watched drug improved patient survival in a lung cancer trial
\n \t

\n
<\/BR>
\n
\n \t

\n
<\/BR><\/p>\n

\n

Akeso, a Chinese biotech with a drug positioned to rival Merck\u2019s megablockbuster Keytruda, has reported for the first time that the therapy can improve patient survival.<\/p>\n

The therapy, ivonescimab, showed a statistically significant survival benefit as a second-line treatment when combined with chemotherapy to treat non-small cell lung cancers. The patients\u2019 cancers had progressed after getting therapies targeting EGFR, a protein that can drive tumor growth.\u00a0<\/p>\n

The company described the results of the Chinese trial as clinically meaningful in a report<\/a> for the first half of the year released on Tuesday. But it didn\u2019t delve into details, which Akeso plans to share at an upcoming medical conference.<\/p>\n

Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n

\t

\n
<\/BR>
\n Jonathan Wosen
\n \t

\n
<\/BR>
\nGo to statnews<\/a>
\n \t

\n
<\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"

STAT+: Akeso says its closely watched drug improved patient survival in a lung cancer trial Akeso, a Chinese biotech with a drug positioned to rival Merck\u2019s megablockbuster Keytruda, has reported for the first time that the therapy can improve patient survival. The therapy, ivonescimab, showed a statistically significant survival benefit as a second-line treatment when […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2159,2280,2152],"tags":[2150],"class_list":["post-6363","post","type-post","status-publish","format-standard","hentry","category-biotech","category-cancer","category-clinical-trials","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/6363"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=6363"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/6363\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=6363"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=6363"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=6363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}